Epizyme Inc
NASDAQ:EPZM
Epizyme Inc
NASDAQ:EPZM
Price:
1.47 USD
Market Closed
Updated:
May 7, 2024
Epizyme Inc
Revenue
|
Epizyme Inc
Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Epizyme Inc
NASDAQ:EPZM
|
Revenue
$53m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Epizyme Inc
Revenue Breakdown
Breakdown by Geography
Epizyme Inc
Epizyme Inc
Not Available
Breakdown by Segments
Epizyme Inc
Epizyme Inc
|
Total Revenue:
37.4m
USD
|
|
Product:
30.9m
USD
|
|
Collaboration Revenue:
6.5m
USD
|
See Also
What is Epizyme Inc's Revenue?
Revenue
53m
USD
53m
USD
Based on the financial report for Jun 30, 2022, Epizyme Inc's Revenue amounts to 53m USD.
What is Epizyme Inc's Revenue growth rate?
Revenue CAGR 5Y
25%
25%
Over the last year, the Revenue growth was 63%. The average annual Revenue growth rates for Epizyme Inc have been 31% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
